Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference

March 24, 2011 By Bio-Medicine.Org

BEDMINSTER, N.J., March 24, 2011 /PRNewswire/ — Omthera
Pharmaceuticals, Inc., a privately-held emerging specialty
pharmaceuticals company, announced today that Jerry Wisler,
President and Chief Executive Officer, will present at the BIO
Windhover/Pharmaceutical Strategic Outlook 2011 Conference at the
Grand Hyatt in New York, on March 31, 2011 at 2:30pm ET.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera
Pharmaceuticals, Inc. is a privately-held, emerging specialty
pharmaceuticals company focusing its efforts on the clinical
development of new therapies for dyslipidemia.  Led by a team
of experts with exceptional experience in developing new therapies
for lipid disorders, Omthera is dedicated to developing innovative
therapies for the millions of patients who have elevated
triglyceride levels and increased risk of cardiovascular
disease.  The Company recently initiated a pivotal Phase III
clinical trial for its lead product candidate, Epanova™, an
Omega-3 fatty acid compound in development as a
triglyceride-lowering adjunct therapy to diet in patients with very
high triglycerides (greater than or equal to 500 mg/dL). Future
planned clinical trials for Epanova include patients with high
triglycerides (greater than or equal to 200 mg/dL and less than or
equal to 500 mg/dL) currently on statin therapy.  Omthera
holds worldwide rights to Epanova under a license from Chrysalis
Pharma AG, a privately held Swiss Company that is the owner of the
product.

For more information, please visit www.omthera.com.Omthera
Contacts:Omthera Media Relations:Douglas Carr

Eric GoldmanFinancial Controller

Rx Communications GroupOmthera Pharmaceuticals

917-322-2563908-741-4323


egoldman@rxir.com

DCarr@Omthera.com

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech